Small Pharma reports positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder
Primary endpoint met. SPL026 demonstrates rapid and durable response.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
